‘Morbius’ Box Office Nets $5.7 Million in Preview Screenings
Sony’s latest addition to its growing film universe of Spider-man characters has officially begun its theatrical run, as Morbius nets $5.7 Million in its preview screenings.
The movie that now holds the dubious distinction as the most delayed film of all-time thanks to the COVID-19 pandemic has officially made its theatrical debut this week.
Jared Leto stars as Michael Morbius, a doctor dedicated to curing an incurable illness, resulting in his transformation into a vampiric monster with an unquenching thirst for human blood.
The film is the latest attempt at Sony to build their very own Marvel Universe around Spider-Man characters; with Morbius following in the footsteps of both Venom and the subsequent Venom: Let There be Carnage.
The film has officially begun its theatrical run with Thursday’s showings giving the studio an idea of the financial implications of the latest sequel.
As reported by ComicBook.com, the Morbius box office has netted $5.7 Million in preview screenings, with the film aiming at an increase heading into its opening weekend.
The initial report notes that screenings for the film began at 4 p.m yesterday, with it opening in more than 3,500 locations, including IMAX theatres.
Projects stood modestly around $30-$50 million for its opening weekend, which would be a positive for the film to begin to attempt to break even through its overall box office run.
Perhaps the biggest fact working against the latest Sony Spider-Verse film is the negative reception it received from the critical community; with the overwhelming majority of those who have seen the movie speaking poorly of its quality.
Fan expectation following the record-breaking Spider-Man: No Way Home seemingly cursed the Sony origin story from the beginning; with fans firmly interested in seeing one of the iconic Spider-Man return to the Sony Universe.
The future of Sony’s universe of Spider-Man characters is seemingly firmly committed to by the studio, but the reality of their underperformance must be noted, as the financial implications of their constant failure should be noticeable at some point.